Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 31.19 USD 1.3% Market Closed
Market Cap: 1B USD
Have any thoughts about
Collegium Pharmaceutical Inc?
Write Note

Collegium Pharmaceutical Inc
Goodwill

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Collegium Pharmaceutical Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
Collegium Pharmaceutical Inc
NASDAQ:COLL
Goodwill
$146m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Goodwill
$44.8B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
8%
Bristol-Myers Squibb Co
NYSE:BMY
Goodwill
$21.8B
CAGR 3-Years
2%
CAGR 5-Years
27%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Goodwill
$68.4B
CAGR 3-Years
11%
CAGR 5-Years
3%
CAGR 10-Years
5%
Merck & Co Inc
NYSE:MRK
Goodwill
$21.7B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Goodwill
$5.8B
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Collegium Pharmaceutical Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
47.46 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Collegium Pharmaceutical Inc's Goodwill?
Goodwill
146m USD

Based on the financial report for Sep 30, 2024, Collegium Pharmaceutical Inc's Goodwill amounts to 146m USD.

What is Collegium Pharmaceutical Inc's Goodwill growth rate?
Goodwill CAGR 1Y
9%

Over the last year, the Goodwill growth was 9%.

Back to Top